keynote-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated aes
Published 1 year ago • 187 plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
2:00
pembrolizumab plus chemotherapy show efficacy for tnbc in keynote-355
-
4:54
hope rugo, md, shares the design and outcomes of keynote-355 presented at sabcs 2020
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
2:01
ascent: sacituzumab govitecan outperforms chemo in black patients with tnbc
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
1:40
keynote-811: trastuzumab chemotherapy with or without pembrolizumab for her2 g/gej cancer
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
0:51
challenges in the treatment of mtnbc
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc